Skip to Main Content

Author Details

Michelle A Ozbun
The University of New Mexico School of Medicine
1993
51
30
Nevan J Krogan (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
37429527The antiviral effects of a MEK1/2 inhibitor promote tumor regression in a preclinical model of human papillomavirus infection-induced tumorigenesis.Antiviral Res2023
36993217Inhibition of Cellular MEK/ERK Signaling Suppresses Murine Papillomavirus Type 1 Replicative Activities and Promotes Tumor Regression.bioRxiv2023
34723633Protamine Sulfate Is a Potent Inhibitor of Human Papillomavirus Infection <i>In Vitro</i> and <i>In Vivo</i>.Antimicrob Agents Chemother2022
36052496Correction: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer.Cancer Res2022
36052495Editor's Note: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer.Cancer Res2022
33481911MEK/ERK signaling is a critical regulator of high-risk human papillomavirus oncogene expression revealing therapeutic targets for HPV-induced tumors.PLoS Pathog2021
33509683Molecular and immune signature of HPV-positive oral cavity squamous cell carcinoma.Oral Oncol2021
34416595The long and winding road: human papillomavirus entry and subcellular trafficking.Curr Opin Virol2021
33422988Infectious titres of human papillomaviruses (HPVs) in patient lesions, methodological considerations in evaluating HPV infectivity and implications for the efficacy of high-level disinfectants.EBioMedicine2021
30981651Extracellular events impacting human papillomavirus infections: Epithelial wounding to cell signaling involved in virus entry.Papillomavirus Res2019
31417185MAPKAPK2 (MK2) inhibition mediates radiation-induced inflammatory cytokine production and tumor growth in head and neck squamous cell carcinoma.Oncogene2019
29440171Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer.Cancer Res2018
30619121Tobacco Exposure Enhances Human Papillomavirus 16 Oncogene Expression via EGFR/PI3K/Akt/c-Jun Signaling Pathway in Cervical Cancer Cells.Front Microbiol2018
28652618Intracellular targeting of annexin A2 inhibits tumor cell adhesion, migration, and in vivo grafting.Sci Rep2017
26799652Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).Autophagy2016
26289843Interaction of human papillomavirus type 16 particles with heparan sulfate and syndecan-1 molecules in the keratinocyte extracellular matrix plays an active role in infection.J Gen Virol2015
24962748Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing.Vaccine2014
25064354Tobacco exposure results in increased E6 and E7 oncogene expression, DNA damage and mutation rates in cells maintaining episomal human papillomavirus 16 genomes.Carcinogenesis2014
25082004Using organotypic (raft) epithelial tissue cultures for the biosynthesis and isolation of infectious human papillomaviruses.Curr Protoc Microbiol2014
23255786Cellular entry of human papillomavirus type 16 involves activation of the phosphatidylinositol 3-kinase/Akt/mTOR pathway and inhibition of autophagy.J Virol2013
23637395Annexin A2 and S100A10 regulate human papillomavirus type 16 entry and intracellular trafficking in human keratinocytes.J Virol2013
22151726Human papillomavirus L2 facilitates viral escape from late endosomes via sorting nexin 17.Traffic2012
22346752Essential roles for soluble virion-associated heparan sulfonated proteoglycans and growth factors in human papillomavirus infections.PLoS Pathog2012
22345461Opposing effects of bacitracin on human papillomavirus type 16 infection: enhancement of binding and entry and inhibition of endosomal penetration.J Virol2012
19896513Inducible heat shock protein 70 enhances HPV31 viral genome replication and virion production during the differentiation-dependent life cycle in human keratinocytes.Virus Res2010
18820705Human and primate tumour viruses use PDZ binding as an evolutionarily conserved mechanism of targeting cell polarity regulators.Oncogene2009
19487298Nitric oxide induces early viral transcription coincident with increased DNA damage and mutation rates in human papillomavirus-infected cells.Cancer Res2009
19214230Two highly conserved cysteine residues in HPV16 L2 form an intramolecular disulfide bond and are critical for infectivity in human keratinocytes.PLoS One2009
18667513Caveolin-1-dependent infectious entry of human papillomavirus type 31 in human keratinocytes proceeds to the endosomal pathway for pH-dependent uncoating.J Virol2008
18834609Virus activated filopodia promote human papillomavirus type 31 uptake from the extracellular matrix.Virology2008
17164289Sumoylation dynamics during keratinocyte differentiation.J Cell Sci2007
17626097Human papillomavirus type 31 uses a caveolin 1- and dynamin 2-mediated entry pathway for infection of human keratinocytes.J Virol2007
17397793The development of quantum dot calibration beads and quantitative multicolor bioassays in flow cytometry and microscopy.Anal Biochem2007
15767396The minor capsid protein L2 contributes to two steps in the human papillomavirus type 31 life cycle.J Virol2005
16353335Using an immortalized cell line to study the HPV life cycle in organotypic "raft" cultures.Methods Mol Med2005
15890923Human papillomavirus type 31b infection of human keratinocytes does not require heparan sulfate.J Virol2005
14769917Propagation of infectious human papillomavirus type 16 by using an adenovirus and Cre/LoxP mechanism.Proc Natl Acad Sci U S A2004
12202253Variable expression of some "housekeeping" genes during human keratinocyte differentiation.Anal Biochem2002
12388811Infectious human papillomavirus type 31b: purification and infection of an immortalized human keratinocyte cell line.J Gen Virol2002
12388689Human papillomavirus type 31b infection of human keratinocytes and the onset of early transcription.J Virol2002
10074210Two novel promoters in the upstream regulatory region of human papillomavirus type 31b are negatively regulated by epithelial differentiation.J Virol1999
9721231Human papillomavirus type 31b E1 and E2 transcript expression correlates with vegetative viral genome amplification.Virology1998
9525589Temporal usage of multiple promoters during the life cycle of human papillomavirus type 31b.J Virol1998
9311816Synthesis of infectious human papillomavirus type 18 in differentiating epithelium transfected with viral DNA.J Virol1997
9188583Characterization of late gene transcripts expressed during vegetative replication of human papillomavirus type 31b.J Virol1997
8764055Transforming growth factor beta1 induces differentiation in human papillomavirus-positive keratinocytes.J Virol1996
7793321Tumor suppressor p53 mutations and breast cancer: a critical analysis.Adv Cancer Res1995
8324748Mutations in p53 are frequent in the preneoplastic stage of mouse mammary tumor development.Cancer Res1993
8448253Glycogen phosphorylase: developmental expression in rat liver.Biol Neonate1993
8453637p53 mutations selected in vivo when mouse mammary epithelial cells form hyperplastic outgrowths are not necessary for establishment of mammary cell lines in vitro.Cancer Res1993
  • 1 - 50 of 51

Recommended Authors

Steven F Gameiro
McMaster Immunology Research Centre, McMaster University
Career Start Year 2017
Number of shared co-authors 0
Farhad Ghasemi
Western University
Career Start Year 2012
Number of shared co-authors 0
Julia Durzynska
Institute of Experimental Biology, Adam Mickiewicz University
Career Start Year 2010
Number of shared co-authors 0
Juan L Callejas-Valera
Cancer Biology Research Center
Career Start Year 2008
Number of shared co-authors 2
Antonio L Amelio
University of North Carolina at Chapel Hill
Career Start Year 2004
Number of shared co-authors 0
Diane M Maher
Sanford Research Center
Career Start Year 2004
Number of shared co-authors 0
Eleonora Forte
Northwestern University Feinberg School of Medicine
Career Start Year 2004
Number of shared co-authors 0
Natalia Issaeva
The University of North Carolina at Chapel Hill
Career Start Year 2002
Number of shared co-authors 2
Danh Tran-Thanh
Centre Hospitalier de l'Universite de Montreal
Career Start Year 2002
Number of shared co-authors 0
Petra Lenz
Frederick National Laboratory for Cancer Research
Career Start Year 1996
Number of shared co-authors 1
J??rgen Haas
University of Edinburgh
Career Start Year 1996
Number of shared co-authors 1
Felicia Goodrum
University of Arizona
Career Start Year 1996
Number of shared co-authors 0
Hongyu Deng
Cancer Research Institute, Central South University
Career Start Year 1995
Number of shared co-authors 1
Mitchell J Frederick
Baylor College of Medicine
Career Start Year 1995
Number of shared co-authors 3
Yu-Tsueng Liu
University of California San Diego
Career Start Year 1994
Number of shared co-authors 0
John W Barrett
University of Western Ontario
Career Start Year 1992
Number of shared co-authors 0
Ren Sun
University of California los angeles
Career Start Year 1992
Number of shared co-authors 2
Matthew D Weitzman
The Children's Hospital of Philadelphia
Career Start Year 1992
Number of shared co-authors 4
Pavel Sova
Altius Institute for Biomedical Sciences
Career Start Year 1990
Number of shared co-authors 0
Jacques Archambault
McGill University
Career Start Year 1990
Number of shared co-authors 3
Joe S Mymryk
University of Western Ontario
Career Start Year 1989
Number of shared co-authors 0
Simon N Stacey
deCODE genetics/Amgen Inc.
Career Start Year 1988
Number of shared co-authors 0
Wendell G Yarbrough
University of North Carolina at Chapel Hill
Career Start Year 1986
Number of shared co-authors 5
Ruud H Brakenhoff
Vrije Universiteit Amsterdam
Career Start Year 1986
Number of shared co-authors 0
John T Schiller
David Geffen School of Medicine at university of california los angeles
Career Start Year 1984
Number of shared co-authors 0
Alfredo A Molinolo
University of California
Career Start Year 1984
Number of shared co-authors 9
Molly Kulesz-Martin
Oregon Health & Science University
Career Start Year 1980
Number of shared co-authors 1
John C Bell
Ottawa Hospital Research Institute
Career Start Year 1979
Number of shared co-authors 2
Thomas E Carey
Kresge Hearing Research Institute, University of Michigan ann arbor
Career Start Year 1976
Number of shared co-authors 1
Arnold J Levine
Simons Center for Systems Biology, Institute for Advanced Study
Career Start Year 1967
Number of shared co-authors 2

Collaborators

Jessica L Smith
Vaccine and Gene Therapy Institute, Oregon Health and Science University
Co-authored papers 4
Umamaheswar Duvvuri
University of Pittsburgh School of Medicine
Co-authored papers 4
Julie E Bauman
George Washington University
Co-authored papers 4
Neil E Bhola
Zai Lab (US) LLC
Co-authored papers 3
Stefan Hartmann
University Hospital Wurzburg
Co-authored papers 3
Toni M Brand
University of Wisconsin School of Medicine and Public Health
Co-authored papers 3
Margaret Soucheray
J. David Gladstone Institutes
Co-authored papers 3
Rachel A O'Keefe
University of California San Francisco
Co-authored papers 3
Daniel E Johnson
University of California San Francisco
Co-authored papers 3
Carolyn Kemp
University of Pittsburgh Medical Center, Eye and Ear Institute
Co-authored papers 3
Yan Zeng
Department of Pharmacy, Affiliated Hospital of North Sichuan Medical College
Co-authored papers 3
Max V Ranall
University of California San Francisco
Co-authored papers 3
Jennifer R Grandis
University of California san francisco
Co-authored papers 3
Sourav Bandyopadhyay
University of California San Francisco
Co-authored papers 3
Nevan J Krogan (CM4AI)
University of California San Francisco
Co-authored papers 3
Gregory N Gan
Co-authored papers 3
Theresa M LaVallee
Parker Institute for Cancer Immunotherapy
Co-authored papers 3
Ian G Mills
Queen's University Belfast
Co-authored papers 1
J. Wade Harper
Harvard Medical School
Co-authored papers 1
Wadih Arap
Rutgers Cancer Institute of New Jersey
Co-authored papers 1
Jan Paul Medema
Oncode Institute
Co-authored papers 1
David M Sabatini
Whitehead Institute for Biomedical Research and Massachusetts Institute of Technology
Co-authored papers 1
Arianna L Kim
Co-authored papers 1
Carlos L??pez-Ot??n
Instituto Universitario de Oncologia, Universidad de Oviedo
Co-authored papers 1
David Sulzer
New York State Psychiatric Institute, Research Foundation for Mental Hygiene
Co-authored papers 1
Ernst J Wolvetang
Australian Institute for Bioengineering and Nanotechnology, University of Queensland
Co-authored papers 1
Manish K Aghi
University of California san francisco
Co-authored papers 1
Juri G Gelovani
Karmanos Cancer Institute (KCI), Wayne State University
Co-authored papers 1
Hirotaka Watada
Co-authored papers 1
Sara Cherry
University of Pennsylvania
Co-authored papers 1
Release 1.2